Clinical Trials Logo

The Metabolic Syndrome clinical trials

View clinical trials related to The Metabolic Syndrome.

Filter by:
  • None
  • Page 1

NCT ID: NCT01000194 Completed - Clinical trials for Cardiovascular Disease

Acute Fatty Acid Intervention Study (AFAST)

AFAST
Start date: January 2008
Phase: N/A
Study type: Interventional

The main objective of this study is to elucidate whether different dietary fatty acids (SFA, PUFA, butter fat and margarine fat) in a high fat load will have different effects on PBMC gene expression profiles. Secondary objectives are to elucidate the effects of these fat loads on individual plasma free fatty acid profiles, triglycerides and cholesterol levels.

NCT ID: NCT00656851 Completed - HIV Infections Clinical Trials

Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome

WU197
Start date: September 2005
Phase: N/A
Study type: Interventional

We hypothesize that the hearts of HIV+ people with The Metabolic Syndrome use and oxidize fats and sugars inappropriately, and that this may impair the heart's ability to pump blood. We hypothesize that exercise training or pioglitazone (Actos) will improve fat and sugar metabolism in the hearts of HIV+ people with The Metabolic Syndrome. This study will advance our understanding of cardiovascular disease in HIV+ people, and will test the efficacy of exercise training and pioglitazone for improving insulin resistance, heart metabolism and heart function in this at risk population.

NCT ID: NCT00405015 Completed - Clinical trials for Ischemia-Reperfusion Injury

The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5 Scintigraphy.

Start date: April 2007
Phase: Phase 2
Study type: Interventional

Cardiovascular disease is the leading cause of death in diabetic patients due to both a high event rate and a worse outcome. A pharmacological intervention that reduces ischemia-reperfusion-injury would improve the outcome of diabetic patients after a cardiovascular event. In the present study, we will use annexinA5 scintigraphy to address the following hypothesis: Rosiglitazone reduces ischemia-reperfusion-injury in humans with insulin resistance.